Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — H1 2025 Earnings Presentation
17 slides from Laboratorio Reig Jofre's earnings presentation, 2025
Slide 1: Financial Results First Half 2025
FINANCIAL RESULTS FIRST HALF 2025
Slide 2: Statement
STATEMENT This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presentati
Slide 3: Contents
CONTENTS → 2025 First half results → Results statement and balance sheet for H1 2025 → RJF stock performance
Slide 4: H1 2025 Briefly
H1 2025 BRIEFLY Key factors in the first half of the year: • Investments aimed at optimizing processes and expanding production capacity to meet global demand by enhancing productivity and efficiency across operations. Efficiency and • Adaptation of the Toledo plant to Annex 1* of the EU GMP. capaci
Slide 5: EMINTECH Project - IPCEI
€25M EMINTECH EMINTECH RJF is an associate member of the project 13 million grant PROJECT - IPCEI European IPCEI (January 2023- from CDTI Med4Cure project August 2026) • EMINTECH Project: addresses two major global health challenges, antimicrobial resistance (AMR) and rare diseases through the devel
Slide 6: Business Units H1 2025
BUSINESS UNITS H1 2025 millions of euros SALES H1 2025 167M -3% € PHARMACEUTICAL 42% SPECIALITY 35% CONSUMER 23% TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC €70.4M / –10% €59.0M / +2% €38.0M / +4% Antibiotics € 25 M Dermatology € 18 M ENT RJ €7M (32 %) +22 % (4 %) Injectables Forté Pharma food €
Slide 7: Business Units H1 2025
BUSINESS UNITS H1 2025 millions of euros SALES H1 2025 €167M -3% PHARMACEUTICAL 42% SPECIALITY 35% CONSUMER 23% TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC €70.4M / -10% €59.0M / +2% €38.0M / +4% • Antibiotics sales declined by 32% due to an • Dermatology grew by +22%, led by sales of • In the fi
Slide 8: International Presence
INTERNATIONAL TOTAL PRESENCE Sed ut perspiciatis SALES H1 2025 Spain Rest of Sed ut perspiciatis Europe Rest of the world SALES GROWTH H1 2025 +70 COUNTRIES € 167 M €71M 43% €77M 46% €19M 11% -6% -1% -2% Rest of Europe Asia 8% 46% Rest of the world 3% RJF continued to reduce its dependence on the Sp
Slide 9: H1 2025 Results
The antibiotics business weighs on an otherwise H1 2025 RESULTS strong first half for REIG JOFRE. Sed ut perspiciatis → The sales number for the first half of 2025 decreased by -3% compared to the same SALES period in 2024 due to a temporary lower production of antibiotics at Pharmaceutical Technolo
Slide 10: Flash Results H1 2025 vs. H1 2024
FLASH RESULTS H1 2025 VS. H1 2024 OPERATING SALES FIGURES NET RESULT RESULT €167.4M €1.5M -3% €1.9M -76% -73% CDMO €28M /+17% EBITDA INNOVATION NFD/EBITDA IN OPERATING CASH RJF continues to INNOVATION IN PRODUCT advance its transition €14.2 INNOVATION IN PRODUCT2.1XSPECIALISED INDUSTRIAL M AND BRAND
Slide 11: Income Statement
INCOME STATEMENT • Turnover dropped by 3% with an associated gross margin of 60%, the same level as the previous year. INCOME STATEMENT (thousand euros) 30/06/2025 30/06/2024 V% Turnover 167.401 172.745 (3%) • Combined personnel expenses and other operating expenses Cost of Sales (67.685) (69.590) (
Slide 12: Balance Sheet: Assets and Investments
BALANCE SHEET INVESTMENTS H1 2025 ASSETS AND INVESTMENTS Millions of euros BALANCE SHEET (thousand euros) 30/06/2025 31/12/2024 INDUSTRIAL Goodwill 26.960 26.809 CAPEX Other intangible assets 53.710 55.285 10.8 Property, plant and equipment 101.427 97.030 Investments in equity-accounted investees 5.
Slide 13: Balance Sheet: Liabilities and Debts
BALANCE SHEET GROSS FINANCIAL DEBT LIABILITIES AND DEBTS 10.4 BALANCE SHEET (thousand euros) 30/06/2025 31/12/2024 74.6 DEBT LEASES APPLICATION IFRS 16 In millions of € In millions of € TOTAL EQUITY 216.385 213.950 DEBT WITH CREDIT INSTITUTIONS + 64.2 OTHER PUBLIC BODIES In millions of € Capital gra
Slide 14: Evolution of Market Capitalisation
EVOLUTION OF MARKET CAPITALISATION €247M RJF YTD SHARES YTD JUN 25 VOLUME CASH RJF (ISIN ES0165359029) €3.01/Share - 30/06/2025 VALUATION maximum minimum 3.9 M €11.2 M €2.85/Share €3.31/Share €2.48/Share YTD Titles YTD SHAREHOLDER COMPOSITION Weighted average 11/06/2025 16/01/2025 31K titles €88K YT
Slide 15: Alternative Performance Measures
ALTERNATIVE PERFORMANCE Management uses certain alternative performance measures in making financial, operating and planning decisions, as well as to evaluate the performance of the Group and MEASURES its subsidiaries. Management believes that these alternative performance measures provide additiona
Slide 16: Links and Complementary Information
LINKS AND INFORMATION → RESULTS WEBCAST COMPLEMENTARY https://reigjofre.com/es/inversores/webcasts/ https://reigjofre.com/es/inversores/presentaciones/ → SUBSCRIPTION CENTRE http://www.reigjofre.com/es/noticias/centro-suscripcion → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre
Slide 17: Thank You
THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN www.reigjofre.com Investor Relations investors@reigjofre.com